34 |
Optimizing the Treatment for Hypertensive Patients Led by Evidence: Is It All about Blood Pressure? |
Jeong Bae Park |
Nov. 09. 07 |
33 |
Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering |
Matthew Worthley |
Nov. 09. 07 |
32 |
Effects of Statin Therapy on Ruptured Coronay Plaque |
Myeong-Ki Hong |
Nov. 09. 07 |
31 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Nov. 02. 07 |
30 |
Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible |
Gregg W. Stone |
Nov. 02. 07 |
29 |
Pushing the Envelope for Bivalirudin Monotherapy: Design, Rationale, and Status of ISARREACT-4 and HORIZONS |
Adnan Kastrati |
Nov. 02. 07 |
28 |
ISAR-CHOICE-2: Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI |
Adnan Kastrati |
Nov. 02. 07 |
27 |
Dual Antiplatelet Therapy: How Long Should It Be Continued after DES Implantation? |
Cheol Whan Lee |
Nov. 02. 07 |
26 |
Triple Antiplatelet Therapy After Drug-Eluting Stenting in Patients with High Risk of Restenosis |
Seong-Wook Park |
Sep. 14. 07 |
25 |
Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data |
Gregg W. Stone |
Sep. 14. 07 |